Markus J Duncan1, Kelly Arbour-Nicitopoulos2, Mehala Subramanieapillai2, Gary Remington3, Guy Faulkner4. 1. University of British Columbia, Vancouver, BC, Canada. Electronic address: mark.duncan@alumni.ubc.ca. 2. University of Toronto, Toronto, ON, Canada. 3. University of Toronto, Toronto, ON, Canada; Centre for Addiction and Mental Health, Toronto, ON, Canada. 4. University of British Columbia, Vancouver, BC, Canada.
Abstract
BACKGROUND: Individuals with schizophrenia tend to have low levels of physical activity (PA) which contributes to high rates of physical comorbidities. Valid and reliable methods of assessing PA are essential for advancing health research. Ten years after initial validation of the Short-Form International Physical Activity Questionnaire (IPAQ), this study expands on the initial validation study by examining retest reliability over a 4-week period, assessing validity with a larger sample, and comparing validity of the IPAQ to a 24-hour recall alternative. METHODS: Participants completed the IPAQ at baseline and 4weeks later, along with a 24-hour PA recall at week 4. At week 3 participants wore waist accelerometers for 7days. Spearman's correlation coefficients and Bland-Altman plots were calculated based on weekly minutes of moderate to vigorous PA (MVPA). RESULTS: Test-retest reliability for the self-administered IPAQ was ρ=0.47, p<0.001 for MVPA. Correlation between IPAQ assessment and accelerometer-determined MVPA was ρ=0.30, p=0.003. The 24-hour recall correlated significantly with MVPA on the previous day ρ=0.27, p=0.012. A Bland-Altman plot indicated the IPAQ-SF underreported by -119.2min (-72%) on average compared to accelerometry (95% limits of agreement -1017.1 to 778.7min, -292% to 147%). CONCLUSION: Compared to previous IPAQ validation work in this population, criterion validity was similar, but reliability was lower over a 4-week period. MVPA criterion validity of the 24-hour recall was comparable to the 7-day self-report IPAQ. Findings further support that the IPAQ is a suitable assessment tool for epidemiological studies. Objective measures of physical activity are recommended for intervention assessment.
BACKGROUND: Individuals with schizophrenia tend to have low levels of physical activity (PA) which contributes to high rates of physical comorbidities. Valid and reliable methods of assessing PA are essential for advancing health research. Ten years after initial validation of the Short-Form International Physical Activity Questionnaire (IPAQ), this study expands on the initial validation study by examining retest reliability over a 4-week period, assessing validity with a larger sample, and comparing validity of the IPAQ to a 24-hour recall alternative. METHODS:Participants completed the IPAQ at baseline and 4weeks later, along with a 24-hour PA recall at week 4. At week 3 participants wore waist accelerometers for 7days. Spearman's correlation coefficients and Bland-Altman plots were calculated based on weekly minutes of moderate to vigorous PA (MVPA). RESULTS: Test-retest reliability for the self-administered IPAQ was ρ=0.47, p<0.001 for MVPA. Correlation between IPAQ assessment and accelerometer-determined MVPA was ρ=0.30, p=0.003. The 24-hour recall correlated significantly with MVPA on the previous day ρ=0.27, p=0.012. A Bland-Altman plot indicated the IPAQ-SF underreported by -119.2min (-72%) on average compared to accelerometry (95% limits of agreement -1017.1 to 778.7min, -292% to 147%). CONCLUSION: Compared to previous IPAQ validation work in this population, criterion validity was similar, but reliability was lower over a 4-week period. MVPA criterion validity of the 24-hour recall was comparable to the 7-day self-report IPAQ. Findings further support that the IPAQ is a suitable assessment tool for epidemiological studies. Objective measures of physical activity are recommended for intervention assessment.
Authors: Mark R Hawes; Kimberly B Roth; Xiaoyan Wang; Ana Stefancic; Christopher Weatherly; Leopoldo J Cabassa Journal: J Health Care Poor Underserved Date: 2020
Authors: Kelly A Aschbrenner; John A Naslund; Amy A Gorin; Kim T Mueser; Emily A Scherer; Mark Viron; Allison Kinney; Stephen J Bartels Journal: Contemp Clin Trials Date: 2018-10-11 Impact factor: 2.226
Authors: Kelly P Arbour-Nicitopoulos; Markus J Duncan; Gary Remington; John Cairney; Guy E Faulkner Journal: Front Psychiatry Date: 2017-08-04 Impact factor: 4.157
Authors: Joseph Firth; Brendon Stubbs; Davy Vancampfort; Felipe B Schuch; Simon Rosenbaum; Philip B Ward; Josh A Firth; Jerome Sarris; Alison R Yung Journal: Schizophr Bull Date: 2018-10-17 Impact factor: 9.306
Authors: Eliška Mičková; Kristýna Machová; Klára Daďová; Ivona Svobodová Journal: Int J Environ Res Public Health Date: 2019-09-11 Impact factor: 3.390
Authors: Alexandra Burton; Kate Walters; Louise Marston; David Osborn Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2020-05-18 Impact factor: 4.328
Authors: Leopoldo J Cabassa; Ana Stefancic; Xiaoyan Wang; Shenyang Guo; Nathaniel Young Lu; Christopher Weatherly Journal: Community Ment Health J Date: 2020-03-28
Authors: S Rosenbaum; R Morell; A Abdel-Baki; M Ahmadpanah; T V Anilkumar; L Baie; A Bauman; S Bender; J Boyan Han; S Brand; S Bratland-Sanda; J Bueno-Antequera; A Camaz Deslandes; L Carneiro; A Carraro; C P Castañeda; F Castro Monteiro; J Chapman; J Y Chau; L J Chen; B Chvatalova; L Chwastiak; G Corretti; M Dillon; C Douglas; S T Egger; F Gaughran; M Gerber; E Gobbi; K Gould; M Hatzinger; E Holsboer-Trachsler; Z Hoodbhoy; C Imboden; P S Indu; R Iqbal; F R Jesus-Moraleida; S Kondo; P W Ku; O Lederman; E H M Lee; B Malchow; E Matthews; P Mazur; A Meneghelli; A Mian; B Morseth; D Munguia-Izquierdo; L Nyboe; B O'Donoghue; A Perram; J Richards; A J Romain; M Romaniuk; D Sadeghi Bahmani; M Sarno; F Schuch; N Schweinfurth; B Stubbs; R Uwakwe; T Van Damme; E Van Der Stouwe; D Vancampfort; S Vetter; A Waterreus; P B Ward Journal: BMC Psychiatry Date: 2020-03-06 Impact factor: 3.630